Tag: prophylacticMastectomy

Articles

• BRCA1 and BRCA2 mutation carriers

News

09/04/12

Contralateral breast cancer has worse prognosis than initial primary

01/10/12

Father's breast cancer or BRCA mutation influences daughter's risk

03/10/10

Breast tissue of high risk women resembles nontumor tissue of patients

Studies

• Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis Cite
  Metcalfe K, Huzarski T, Gronwald J, Kotsopoulos J, Kim R, Moller P, et al. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-023-02503-8
• Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC) Cite
  Madrigal LF, Garcé MYR, Ruiz FJJ. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC). Current Problems in Cancer. Elsevier BV; 2023;:101008 10.1016/j.currproblcancer.2023.101008
• Breast Cancer Genes and Contralateral Prophylactic Mastectomy: Beyond BRCA Cite
  Tuttle TM, Hui JYC. Breast Cancer Genes and Contralateral Prophylactic Mastectomy: Beyond BRCA. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14161-4
• 157P Comparison of survival outcomes in young patients with breast cancer receiving contralateral prophylactic mastectomy versus unilateral mastectomy Cite
  Huang H. 157P Comparison of survival outcomes in young patients with breast cancer receiving contralateral prophylactic mastectomy versus unilateral mastectomy. ESMO Open. Elsevier BV; 2023; 8:101497 10.1016/j.esmoop.2023.101497
• Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review Cite
  Bertozzi S, Londero AP, Xholli A, Azioni G, Di Vora R, Paudice M, et al. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. Journal of Clinical Medicine. MDPI AG; 2023; 12:1422 10.3390/jcm12041422
• Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I–III unilateral breast cancer in the USA, 1998–2016 Cite
  Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I–III unilateral breast cancer in the USA, 1998–2016. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06397-z
• Effect of Contralateral Prophylactic Mastectomy on Overall Survival in Patients with Hormone Receptor Negative Breast Cancer Cite
  Su YC, Zheng X. Effect of Contralateral Prophylactic Mastectomy on Overall Survival in Patients with Hormone Receptor Negative Breast Cancer. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-674088/v1
• Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis Cite
  Metcalfe KA, Price MA, Mansfield C, Hallett DC, Lindeman GJ, Fairchild A, et al. Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:268-274 10.1038/s41416-020-0861-3
• Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study Cite
  Rettenmaier MA, Micha JP, Bohart R, Epstein HD, King MM, Goldstein BH. Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study. Journal of Gynecologic Surgery. Mary Ann Liebert Inc; 2020; 36:189-193 10.1089/gyn.2019.0135
• Abstract P5-08-08: Risk reducing mastectomy in average and high risk patients with locally advanced triple negative breast cancer Cite
  Stjepanovic N, Giffoni D, Gandhi S, Jerzak K, Lemon S, Ott K, et al. Abstract P5-08-08: Risk reducing mastectomy in average and high risk patients with locally advanced triple negative breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p5-08-08
• Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers Cite
  Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Noguès C, et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-1247-4
• Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015 Cite
  Kurian AW, Canchola AJ, Ma CS, Clarke CA, Gomez SL. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. Cancer. Wiley; 2019; 126:958-970 10.1002/cncr.32618
• Growing Trends of Contralateral Prophylactic Mastectomy and Reconstruction in Young Breast Cancer Cite
  Chen H, Zhang P, Zhang M, Wang M, Bai F, Wu K. Growing Trends of Contralateral Prophylactic Mastectomy and Reconstruction in Young Breast Cancer. Journal of Surgical Research. Elsevier BV; 2019; 239:224-232 10.1016/j.jss.2019.02.002
• No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma Cite
  Yu T, Liu Y, Hu X, Di G. No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma. Journal of Surgical Oncology. Wiley; 2018; 118:928-935 10.1002/jso.25221
• "What if I keep my breasts?" Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study. Cite
  Warner E, Zhu S, Hill K, Causer P, Jong RA, Yaffe M, et al. "What if I keep my breasts?" Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1523-1523 10.1200/jco.2018.36.15_suppl.1523
• Risk-reducing mastectomy for the prevention of primary breast cancer Cite
  Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database of Systematic Reviews. Wiley; 2018; 10.1002/14651858.cd002748.pub4
• BRCA1 risk-reducing surgery appears to reduce risk of developing breast cancer Cite
  Irwin G, Hinds G, McFaul L, Morrison P, Harley I, McIntosh S. BRCA1 risk-reducing surgery appears to reduce risk of developing breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:S4 10.1016/j.ejso.2018.01.236
• The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy Cite
  Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:263-267 10.1007/s10549-017-4476-1
• Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ Cite
  Park HL, Chang J, Lal G, Lal K, Ziogas A, Anton-Culver H. Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ. Clinical Breast Cancer. Elsevier BV; 2018; 18:e179-e185 10.1016/j.clbc.2017.08.001
• Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Cite
  Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2889-2897 10.1245/s10434-017-5931-2
• Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033) Cite
  Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, et al. Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0752-y
• Abstract P6-10-17: Rates of prophylactic surgeries among BRCA 1 or 2 mutation carriers: A single institution experience Cite
  Raphael J, Hewitt P, Graham T, Ott K, Mancuso T, Lorentz J, et al. Abstract P6-10-17: Rates of prophylactic surgeries among BRCA 1 or 2 mutation carriers: A single institution experience. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p6-10-17
• Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta‐Analysis Cite
  Nagaraja V, Edirimanne S, Eslick GD. Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta‐Analysis. The Breast Journal. Wiley; 2016; 22:158-165 10.1111/tbj.12549
• Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis Cite
  Portschy PR, Kuntz KM, Tuttle TM. Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106:dju160-dju160 10.1093/jnci/dju160
• Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis Cite
  Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. BMJ; 2014; 348:g226-g226 10.1136/bmj.g226
• Biology, Treatment, and Outcome in Very Young and Older Women with DCIS Cite
  Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, et al. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 19:3777-3784 10.1245/s10434-012-2413-4
• P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis. Cite
  Shapira I, Budman D, Akerman M, Weiselberg L, Vinciguerra V, D'Olimpio J, et al. P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis.. Poster Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-p2-13-02
• Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study. Cite
  Junqueira MJ, Morrow M, Reiner AS, Malone K, Lynch C, Bernstein JL. Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1014-1014 10.1200/jco.2011.29.15_suppl.1014
• 500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival? Cite
  Heemskerk-Gerritsen B, Hooning M, Jager A, Tilanus-Linthorst M, Bartels C, van den Ouweland A, et al. 500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?. European Journal of Cancer Supplements. Elsevier BV; 2010; 8:206 10.1016/s1359-6349(10)70521-8
• Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile Cite
  Graham K, de las Morenas A, Tripathi A, King C, Kavanah M, Mendez J, et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 102:1284-1293 10.1038/sj.bjc.6605576
• Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients Cite
  Bedrosian I, Hu C, Chang GJ. Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:401-409 10.1093/jnci/djq018
• A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women Cite
  Fryzek JP, Ye W, Nyrén O, Tarone RE, Lipworth L, McLaughlin JK. A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2005; 97:131-134 10.1007/s10549-005-9099-2
• Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy Cite
  Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, et al. Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy. Journal of the American College of Surgeons. Elsevier BV; 2009; 209:746-752 10.1016/j.jamcollsurg.2009.08.010